Efficacy and Safety of Bendamustine-Rituximab for Nodular Lymphocyte Predominant Hodgkin Lymphoma.

ABSTRACT:

Introduction

Bendamustine-rituximab (BR) has demonstrated efficacy and tolerability in the treatment of various indolent B-cell lymphomas, but there is limited data regarding its outcomes in nodular lymphocyte predominant B-cell (Hodgkin) lymphoma (NLPBL).

Methods

This retrospective, population-based study included consecutive patients ≥ 18 years old who received BR for NLPBL in Alberta, Canada.

Results

The study population comprised 23 patients with a median age of 39 years (range 18-74) who received BR for treatment-naive (n = 17) or relapsed/refractory (n = 6) NLPBL. Advanced stage disease was present in 18 (78%), splenic involvement in 9 (39%), and bone marrow involvement in 8 (35%) patients. The response rate to BR was 100%, with a complete response in 78% and a

SUBMITTER: Robin A 

PROVIDER: S-EPMC12319886 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature